Hold on to your shares: AbCellera Biologics Inc (ABCL) Stock
The Benchmark Company raised the price target for the AbCellera Biologics Inc (NASDAQ:ABCL) stock from “a Hold” to “a Buy”. The rating was released on February 22, 2024, according to finviz. The stock was resumed by Piper Sandler, who disclosed in a research note on October 13, 2023, to Overweight and set the price objective […]
A healthy upside potential exists for AbCellera Biologics Inc (ABCL) Stock
The Benchmark Company raised the price target for the AbCellera Biologics Inc (NASDAQ:ABCL) stock from “a Hold” to “a Buy”. The rating was released on February 22, 2024, according to finviz. The stock was resumed by Piper Sandler, who disclosed in a research note on October 13, 2023, to Overweight and set the price objective […]
A positive surprise is on the way: AbCellera Biologics Inc (ABCL) Stock
The Benchmark Company raised the price target for the AbCellera Biologics Inc (NASDAQ:ABCL) stock from “a Hold” to “a Buy”. The rating was released on February 22, 2024, according to finviz. The stock was resumed by Piper Sandler, who disclosed in a research note on October 13, 2023, to Overweight and set the price objective […]
AbCellera Biologics Inc (ABCL) Stock is Just Right Size-Neither Too Big Nor Too Small
The Benchmark Company raised the price target for the AbCellera Biologics Inc (NASDAQ:ABCL) stock from “a Hold” to “a Buy”. The rating was released on February 22, 2024, according to finviz. The stock was resumed by Piper Sandler, who disclosed in a research note on October 13, 2023, to Overweight and set the price objective […]
A fresh round of sideways trading continues for AbCellera Biologics Inc (ABCL) Stock.
The Benchmark Company raised the price target for the AbCellera Biologics Inc (NASDAQ:ABCL) stock from “a Hold” to “a Buy”. The rating was released on February 22, 2024, according to finviz. The stock was resumed by Piper Sandler, who disclosed in a research note on October 13, 2023, to Overweight and set the price objective […]
Does AbCellera Biologics Inc (ABCL) Stock have a positive outlook following recent trade?
The Benchmark Company raised the price target for the AbCellera Biologics Inc (NASDAQ:ABCL) stock from “a Hold” to “a Buy”. The rating was released on February 22, 2024, according to finviz. The stock was resumed by Piper Sandler, who disclosed in a research note on October 13, 2023, to Overweight and set the price objective […]
The Technical Story of AbCellera Biologics Inc (ABCL) Stock
The Benchmark Company raised the price target for the AbCellera Biologics Inc (NASDAQ:ABCL) stock from “a Hold” to “a Buy”. The rating was released on February 22, 2024, according to finviz. The stock was resumed by Piper Sandler, who disclosed in a research note on October 13, 2023, to Overweight and set the price objective […]
AbCellera Biologics Inc (ABCL) Stock Is Looking Attractive
The Benchmark Company raised the price target for the AbCellera Biologics Inc (NASDAQ:ABCL) stock from “a Hold” to “a Buy”. The rating was released on February 22, 2024, according to finviz. The stock was resumed by Piper Sandler, who disclosed in a research note on October 13, 2023, to Overweight and set the price objective […]
